This biotech stock is an 'oncology powerhouse' with 40% upside, says Truist Securities
- Posted on January 10, 2025
- By CNBC
- 2 Views
This biotech stock is an 'oncology powerhouse' with 40% upside, says Truist Securities
The firm's 12-month price target on the Nasdaq-traded shares of the German company is $172.
